← Evidence library

BIB_366

KEYNOTE-716 secondary analysis: adjuvant pembrolizumab REDUCES non-melanoma skin cancer but does NOT reduce new primary melanoma (Stage IIB/IIC, n=976, 52.8-mo FU).

Evidence grade

A

Tier

1 (JAMA Network Open; KEYNOTE-716 = practice-chan

Cited by tasks

5, 5a, 7, 17, 19a

Identifiers

PMC12914490 · DOI:10.1001/jamanetworkopen

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_366/findings.md (research corpus). This page is a short context summary — not individualised medical advice.